Fig. 1: Survival outcomes by age.
From: Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
PFS (a) and OS (b) of patients ≥65 or <65 years; PFS (c) and OS (d) of patients aged 65–69, 70–74, and ≥75 years; age effects on PFS by LDH (e, f), CAR product used (g, h), and bridging (i, j) (left panels e, g, i ≥ 65 years; right panels f, h, j < 65 years). Comparisons were made by Log-rank tests.
